Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

First Wave files IND for enhanced microgranule delivery of adrulipase

First Wave BioPharma (NASDAQ:FWBI) submitted an IND application seeking authorization from the FDA to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic...

November 30, 2022

Developments

Context Therapeutics selects antibody for Claudin 6-positive solid tumors

Context Therapeutics (NASDAQ:CNTX) announced the selection of CTIM-76, a T-cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, resulting from its...

November 29, 2022

Developments

PharmaJet receives NIH grant for HPV needle-free immunization study

Closely-held PharmaJet received an $800,000-plus direct to Phase 2 grant from the NIH to evaluate the immunogenicity of intradermal administration of human papilloma virus (HPV) vaccine using the company’s Tropis...

November 29, 2022

Developments

Enrollment tops 25% in Femasys FemaSeed de novo trial

Femasys (NASDAQ:FEMY) completed more than 25% of its targeted enrollment of 214 patient fertility cycles in its FemaSeed de novo trial. FemaSeed is the first and only first-line approach in development designed to...

November 29, 2022

Developments

FDA grants fast tract to Aravive’s batiraxcept for ccRCC

The FDA granted fast track designation to Aravive’s (NASDAQ:ARAV) lead program, batiraxcept, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after...

November 29, 2022

Executive Moves

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...

November 29, 2022

Markets

Stifel starts OmniAb at buy; PT $12

Stifel launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and $12 price target. The stock closed at $2.61 on Nov. 25. Analyst Stephen Willey writes that OmniAb represents the construction of a high-throughput...

November 28, 2022

Markets

HCW ups BerGenBio to buy on positive outlook for bemcentinib

H.C. Wainwright upgraded BerGenBio (OSLO:BGBIO) to “buy” from “neutral” with a price target of NOK30. The stock closed at NOK6.70 on Nov. 25. “As 2022 is coming to a close, we believe now is an opportune time to step...

November 28, 2022

Developments

TC BioPharm begins dosing Phase 2b AML study

TC BioPharm (NASDAQ:TCBP) began dosing the first three patients in its Phase 2b ACHIEVE clinical trial of OmnImmune, an allogeneic unmodified cell therapy focused on treating acute myeloid leukemia (AML). The initial...

November 22, 2022

Developments

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

The FDA granted fast tract designation to Palisade Bio’s (NASDAQ:PALI) LB1148 for the acceleration of time to return of bowel function following surgery. By inhibiting the activity of digestive proteases, the company...

November 22, 2022

Markets

Maxim starts Cingulate at buy; PT $3

Maxim Group launched coverage of Cingulate (NASDAQ:CING) with a “buy” rating and price target of $3. The stock closed at 69 cents on Nov. 21. Cingulate is a Phase 3-ready company developing multiple therapies for...

November 22, 2022

Markets

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

November 22, 2022

First Wave files IND for enhanced microgranule delivery of adrulipase

Context Therapeutics selects antibody for Claudin 6-positive solid tumors

PharmaJet receives NIH grant for HPV needle-free immunization study

Enrollment tops 25% in Femasys FemaSeed de novo trial

FDA grants fast tract to Aravive’s batiraxcept for ccRCC

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Stifel starts OmniAb at buy; PT $12

HCW ups BerGenBio to buy on positive outlook for bemcentinib

TC BioPharm begins dosing Phase 2b AML study

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

Maxim starts Cingulate at buy; PT $3

SVB starts Trevi Therapeutics at OP; PT $6

General

More